AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|
28.8 C
New York
Thursday, July 2, 2026

Tag: actions

newssourceFORcompanyinformationcontent1releasesmarket

CODI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Compass Diversified Holdings Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Compass Diversified Holdings (“Compass” or “the Company”) (NYSE: CODI) and certain of its officers.

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a...

RDDT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Reddit, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reddit, Inc. (“Reddit” or “the Company”) (NYSE: RDDT) and certain of its officers.

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

RIBER: Descriptif du programme du programme de rachat d’actions

Mise en œuvre du programme de rachat d’actions

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

BIC : Rémunération d’un mandataire social

                           

Compagnie de l’Odet : mise à disposition du descriptif du programme de rachat d’actions

COMPAGNIE DE L'ODET

Notice on the Extraordinary General Meeting of Shareholders of the AUGA group, AB entity under restructuring on 14 July 2025 to approve the Company’s...

AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the “Company”), by the initiative and decision of the Board, is convening an Extraordinary General meeting of shareholders on July 14, 2025, at 10:00 a.m., where the Company’s shareholders will vote on the approval of the Company’s draft restructuring plan, hereinafter referred to as the “Meeting”.

SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud — Contact BFA Law (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsActions

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers